Abbott FreeStyle Libre 4 Launches in China: AI Closed-Loop Insulin System Frees Diabetics from Finger Pricks

Overview

Abbott today officially launches FreeStyle Libre 4 continuous glucose monitoring system in China. Simultaneously announces open-source AI insulin closed-loop system SugarBot cooperation with Tsinghua University Medical School. Chinese diabetics lead the way into the "self-driving" blood glucose management era.

Working Principle

FreeStyle Libre 4 works with insulin pump and AI algorithm to form a complete closed-loop control system:

1. Libre 4 automatically measures tissue fluid glucose concentration every 5 minutes
2. SugarBot AI calculates required insulin dosage based on glucose data, meal plans, and exercise status
3. Insulin pump automatically injects basal rate and bolus
4. No manual patient operation required throughout

This system is vividly called "blood glucose self-driving" by diabetics.

Clinical Data

Peking Union Medical College Hospital led Asia's largest closed-loop system clinical trial:

• Time in Range (TIR) improved from 62% to 83%
• Severe hypoglycemia events reduced 76%
• Patient quality of life score improved 41%
• HbA1c dropped an average of 0.9%

China's Diabetic Population

China has the largest diabetic population globally with over 140 million adults. Complications from poor blood glucose management incur annual medical expenditures exceeding 600 billion RMB.

Price and Accessibility

Libre 4 sensor costs 420 RMB each, usable for 14 days, monthly cost about 900 RMB. Full insulin pump plus closed-loop system costs 30,000-80,000 RMB.

Now included in 8 provincial and municipal medical insurance reimbursement lists including Beijing, Shanghai, Zhejiang. Patient copay ratio drops to within 30%.